Personalis has secured its fourth Medicare coverage decision for its advanced cancer test, expanding its use to pre-surgical breast cancer treatment and intensifying its rivalry with Natera in the growing liquid biopsy market.
Back
Personalis Wins 4th Medicare Nod for Breast Cancer Test
Personalis Inc. received expanded Medicare coverage for its NeXT Personal minimal residual disease (MRD) test, opening the door for its use in monitoring neoadjuvant therapy for high-risk breast cancer patients before they undergo surgery. The decision marks the fourth Medicare coverage milestone for the company's liquid biopsy technology.
"Securing our fourth Medicare coverage decision for NeXT Personal is another milestone that moves our technology into active treatment management," Chris Hall, Chief Executive Officer of Personalis, said. "We are focused on enabling a better outcome for patients by using our ultrasensitive MRD technology to help guide decisions throughout their clinical journey."
The new coverage applies to patients with Stage II-III Triple-Negative Breast Cancer (TNBC) or HER2-positive breast cancer. It is supported by data from the PREDICT-DNA study, which showed the test could accurately track therapy response and predict outcomes better than traditional methods. Notably, the study found nearly half of all cancer DNA detections after therapy were at levels below 100 parts per million (PPM), a range missed by less sensitive assays.
For investors, this expanded coverage validates the clinical utility of NeXT Personal and moves Personalis into the active treatment management market, a strategic shift from post-surgical monitoring. The decision could accelerate adoption and revenue growth for Personalis, which has a market capitalization of $85 million, but it also comes as competition in the MRD space heats up.
The Ultrasensitive Advantage
Personalis's NeXT Personal test is designed to provide a highly sensitive and specific view of a patient's cancer by tracking up to 1,800 patient-specific genetic variants. This high-resolution approach is critical in the neoadjuvant setting, where treatment decisions are made in a narrow window before surgery.
"The clinical data published in JCO clearly show that neoadjuvant monitoring benefits from a highly quantitative, ultrasensitive test to capture treatment response dynamics," Richard Chen, President and Chief Medical Officer at Personalis, said. The company argues that the ability to detect cancer traces at extremely low levels is a key differentiator, allowing physicians to more confidently assess if a therapy is working.
A Crowding MRD Market
The expanded coverage for Personalis comes as the entire field of MRD testing gains momentum and attracts more competition. Just last month, rival Natera Inc. announced that the U.S. Food and Drug Administration had approved its Signatera test as the first blood-based companion diagnostic for an immunotherapy in muscle-invasive bladder cancer.
Natera's approval, which was tied to Genentech's Tecentriq and supported by the global IMvigor011 trial, represents a major milestone for the industry. While Personalis's news is a significant win in the breast cancer space, Natera's broader regulatory and commercial footprint, with Medicare coverage across six cancer types, makes it a formidable competitor. The developments highlight a broader shift in oncology toward personalized, MRD-guided care, creating a large market opportunity that is attracting multiple well-funded players.
This article is for informational purposes only and does not constitute investment advice.
[1] Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring[2] A Safety Proposal for AI-Enabled Medical Devices[3] New Research Sheds Light on the Risks and Realities of Fragmented Workforce Communication in the AI Era[4] Signatera CDx Gets FDA Nod as Companion Diagnostic for Muscle-Invasive Bladder Cancer
© 2026 Edgen Powered by